|
|
|
|
|
| May 27,
2010 | ISSUE NUMBER 150 VOL 8 |
Mergers & Acquisitions
Abbott Shells Out $3.7 Billion for Piramal
Abbott and Piramal decide who’s on first in India, whose pharma market is booming—for generics makers.
Emerging Markets
WHO Threatens Industry Shut-out on Counterfeit Regulation
Brazil and India pushed hard at the World Health Assembly for a resolution to curb pharma from over-labeling their generics as counterfeit and restricting market access. But it’s a fine line between eliminating bias and discouraging innovation.
Advertisement:
Does anybody in Life Sciences do Call & Territory Planning?
It’s been a problem for years, so you have to see this! Using update’s virtually automatic CRM tool means being analytical and efficient while rewarding for the reps. Speed, efficiency, convenience, and intelligence, for optimal business results and a better ROI. Take a look at business cases, the functionality and advantages that make you more competitive than ever! Join the free webinar –
 Register NOW!
|
Digital
Pharma Digital Smarts Quantified in IQ Index
The top brand in a think tank L2 and PHD Network survey on digital competence is Pfizer’s Viagra, but a MENSA spot might be premature at this point.
Regulatory
Post-Approval Regulatory Priorities: Progress or Pile-Up?
Innovation in industry has always required a strong internal champion—the danger is a process led by the bland and risk-averse.
|
| 
|
 // Qualitest Pharmaceuticals hired Robert Mills as president.
// Hiru, after a merger with Jiangxi China Shuang Shi, appointed Xiao Cheii Liu chairman and CEO, Xiang Ling Zhu CFO, and Xue Song Xie general manager.
// John Mendlein joined aTyr Pharma’s board as executive chairman.
// Techne gave Roeland Nusse a seat on its board.
// Mikael Dolsten, Wyeth’s head of R&D before its merger with Pfizer, was appointed president of worldwide research and development.
// AstraZeneca appointed Martin Mackay to the newly-created position of president of R&D.
// |
Advertisement:
The Health Care Reform Opportunity: Implications and Recommendations for Life Sciences
Is health care reform a tough pill to swallow for your business? Although reform is changing the landscape, it is rife with opportunity. A report from Capgemini Consulting examines the challenges and implications resulting from health care reform and offers recommendations on how capitalize on the shifts within the industry.
 Download here
|
|
May 25 Moving Beyond Document Management to Enterprise Content Compliance
11:00 AM ET; 8:00 AM PT
Register Free at pharmexec.com/moving
|
Advertisement:
Safety Document Exchange in the Global Clinical Research Environment
Serious Adverse Event (SAE) reporting can have severe repercussions both for patient safety and company reputation. By choosing a portal solution from a SaaS provider with state-of-the-art online security features, a sponsor or CRO can maintain real-time distribution and access reports for all documents shared, helping maintain compliance and data privacy.  View Whitepaper
|
|
May 24–27 Contract Lifecycle Management– I-many Summit 2010 User Conference
Miami, FL
June 13–17, 2010 Drug Industry Association’s Annual Meeting
Washington DC
Jun 22–23 Disease Education and Bio/Pharmaceutical Product Promotion Using Social Media Tools
Alexandria, VA
Jun 28–29 Clinical R&D Compliance Forum
Philadelphia, PA
Jul 26–27 Bio/Pharmaceutical Summit: Optimize Market Research and to Drive Accurate Product Forecasts
Philadelphia, PA
Jul 29–30 5th Annual Congress on Clinical Supply Chain Management
Princeton, NJ
Sep 9–10 Clinical Trials in Latin America
Lima, Peru
Sep 29–30 6th Annual Bio/Pharmaceutical and Medical Device Product Recalls Summit
Washington, DC
Oct 5–6 International Diabetes Summit
Dubai, UAE
|
|
|
|
 |
|
 |
|
 |
| If you plan to enter emerging markets over the next 3 years, what will be your primary entry strategy? |
|
|
|
|
You
are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.
To
ensure delivery to your Inbox, please add us to your
address book. If you need help doing this, click
here.
Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.
|
|
